Bromide

Bromide

SCHEMBL3848606

Cc1sc[n+](CC(=O)c2ccc3ccccc3c2)c1C.[Br-]

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 known ✓ P35372 1/20 0.43
KMT2A Q03164 5/20 0.64
KDM4E B2RXH2 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
HPGD P15428 2/20 0.47
PTPN1 P18031 1/20 0.47
NPC1 O15118 3/20 0.45
ALDH1A1 P00352 3/20 0.45
RAB9A P51151 2/20 0.45
MAPT P10636 3/20 0.44
MEN1 O00255 2/20 0.44
OPRD1 P41143 1/20 0.43
POLB P06746 2/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
NPSR1 Q6W5P4 2/20 0.41
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
RAD52 P43351 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL3848882 0.84 OPRM1 (0.52) KMT2AKDM4ESMN1; SMN2HPGDPTPN1
Alagebrium SCHEMBL1648822 0.83 KMT2A (0.74) KMT2AKDM4ESMN1; SMN2HPGDALDH1A1
Bromide SCHEMBL3845051 0.83 KMT2A (0.61) KMT2AKDM4ESMN1; SMN2ALDH1A1MAPT
SCHEMBL6933448 0.83 OPRM1 (0.50) KMT2AKDM4ESMN1; SMN2HPGDPTPN1
Alagebrium SCHEMBL1820212 0.82 KMT2A (0.71) KMT2AKDM4ESMN1; SMN2HPGDNPC1
SCHEMBL6535048 0.81 KMT2A (0.59) KMT2AKDM4ESMN1; SMN2ALDH1A1MAPT
Bromide SCHEMBL3854076 0.81 KMT2A (0.71) KMT2AKDM4ESMN1; SMN2HPGDPTPN1
Alagebrium SCHEMBL225618 0.80 KMT2A (0.69) KMT2AKDM4EALDH1A1MAPTMEN1
Bromide SCHEMBL3845600 0.79 KMT2A (0.76) KMT2AKDM4EPTPN1NPC1ALDH1A1
Bromide SCHEMBL3849441 0.79 KMT2A (0.63) KMT2AKDM4ESMN1; SMN2NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021125905-A1 NOVEL THIAZOLE DERIVATIVE AND USE THEREOF 가천대학교 산학협력단 2021-06-24 WO disclosed
EP-2085086-A2 Method for treating congestive heart failure or diabetic nephropathy Synvista Therapeutics, Inc. (US) 2009-08-05 EP disclosed
US-20090124674-A1 Method for treating congestive heart failure SYNVISTA THERAPEUTICS, INC. (US) 2009-05-14 US disclosed
US-20090124673-A1 Method for treating diabetic nephropathy SYNVISTA THERAPEUTICS , INC. (US) 2009-05-14 US disclosed
US-7432254-B2 Method for treating glaucoma IC SYNVISTA THERAPEUTICS, INC. (US) 2008-10-07 US disclosed
EP-1353669-B1 METHOD FOR TREATING GLAUCOMA ALTEON INC (US) 2007-08-15 EP disclosed
US-7166625-B2 Method for treating fibrotic diseases and other indications ALTEON, INC. (US) 2007-01-23 US disclosed
EP-1305024-A4 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC ALTEON INC (US) 2006-03-22 EP disclosed
EP-1353669-A4 METHOD FOR TREATING GLAUCOMA IB ALTEON INC (US) 2005-10-19 EP disclosed
US-20040235837-A1 Method for treating fibrotic diseases or other indications IE SYNVISTA THERAPEUTICS, INC. 2004-11-25 US disclosed
EP-1353669-A1 METHOD FOR TREATING GLAUCOMA IB Alteon, Inc. (US) 2003-10-22 EP disclosed
EP-1305024-A1 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC Alteon, Inc. (US) 2003-05-02 EP disclosed
US-20020177586-A1 Method for treating fibrotic diseases or other indications ID SYNVISTA THERAPEUTICS, INC. 2002-11-28 US disclosed
US-20020160993-A1 Method for treating glaucoma IC SYNVISTA THERAPEUTICS, INC. 2002-10-31 US disclosed
WO-2002053158-A1 METHOD FOR TREATING GLAUCOMA IB ALTEON, INC. (US) 2002-07-11 WO disclosed
US-20020068729-A1 Method for treating fibrotic diseases or other indications IC ALTEON, INC. 2002-06-06 US disclosed
WO-2002007725-A1 METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC ALTEON, INC. (US) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235837-A1 Method for treating fibrotic diseases or other indications IE MMP1, COL1A1, COL2A1 OPRM1 3301/4885KMT2A 4599/4885KDM4E 3755/4885
US-20020160993-A1 Method for treating glaucoma IC CHAT, MYOC, GAP43 OPRM1 2517/4885KMT2A 4535/4885KDM4E 4361/4885
US-20020068729-A1 Method for treating fibrotic diseases or other indications IC MMP1, COL1A1, COL2A1 OPRM1 3255/4885KMT2A 4545/4885KDM4E 3863/4885
US-20090124673-A1 Method for treating diabetic nephropathy REN, SLC5A2, SLC5A1 OPRM1 1647/4885KMT2A 4493/4885KDM4E 3627/4885
US-20020177586-A1 Method for treating fibrotic diseases or other indications ID MMP1, COL1A1, COL2A1 OPRM1 3035/4885KMT2A 4326/4885KDM4E 3355/4885
US-20090124674-A1 Method for treating congestive heart failure TNNI3, TNNT2, FABP3 OPRM1 1579/4885KMT2A 4520/4885KDM4E 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.